Journal of Tissue Engineering and Reconstructive Surgery >

2020 , Vol. 16 >Issue 3: 198 - 200

DOI: https://doi.org/10.3969/j.issn.1673-0364.2020.03.006

Case Report: Clinical Attempt of Targeted Therapy for Complex Venous Malformations

Expand
  • Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

Received date: 2020-04-16

  Revised date: 2020-04-29

  Online published: 2020-06-26

Fold

Abstract

The management of severe and complicated venous malformation is still not standardized currently. Sirolimus has been reported to successfully treat complicated vascular anomalies in many case reports and clinical trials recently. One case of extremely severe and complicated venous malformation of right upper limb and trunk was described. After 2 years of oral treatment with sirolimus, the lesion was significantly resolved, and no obvious recurrence was found after 1 year of follow-up.

Key words： Venous malformation; Sirolimus; Vascular malformation; Target therapy

Cite this article

Hongyuan LIU, Xi YANG, Hao GU, Li HU, Yi SUN, hui CHEN, Xiaoxi LIN . Case Report: Clinical Attempt of Targeted Therapy for Complex Venous Malformations[J]. Journal of Tissue Engineering and Reconstructive Surgery, 2020 , 16(3) : 198 -200 . DOI: 10.3969/j.issn.1673-0364.2020.03.006

References

[1] 中华医学会整形外科分会血管瘤和脉管畸形学组. 血管瘤和脉管畸形的诊断及治疗指南(2019版)[J]. 组织工程与重建外科杂志, 2019,15(5):277-317.
[2] Freixo C, Ferreira V, Martins J , et al. Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review[J]. J Vasc Surg, 2020,71(1):318-327.
[3] Soblet J, Kangas J, Natynki M , et al. Blue rubber bleb nevus (BRBN) syndrome is caused by somatic TEK (TIE2) mutations[J]. J Invest Dermatol, 2017,137(1):207-216.
[4] Castel P, Carmona FJ, Grego-Bessa J , et al. Somatic PIK3CA mutations as a driver of sporadic venous malformations[J]. Sci Transl Med, 2016, 8(332):332ra42.
[5] Adams DM, Trenor CC 3rd, Hammill AM, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies[J]. Pediatrics, 2016,137(2):e20153257.
[6] Hammer J, Seront E, Duez S , et al. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study[J]. Orphanet J Rare Dis, 2018,13(1):191.
[7] Hammill AM, Wentzel M, Gupta A , et al. Sirolimus for the treatment of complicated vascular anomalies in children[J]. Pediatr Blood Cancer, 2011,57(6):1018-1024.
[8] Lackner H, Karastaneva A, Schwinger W , et al. Sirolimus for the treatment of children with various complicated vascular anomalies[J]. Eur J Pediatr, 2015,174(12):1579-1584.
[9] Morelon E, Stern M, Israel-Biet D , et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients[J]. Transplantation, 2001,72(5):787-790.
[10] Russell TB, Rinker EK, Dillingham CS , et al. Pneumocystis jirovecii pneumonia during sirolimus therapy for kaposiform hemangioendo the lioma[J]. Pediatrics, 2018,141(Suppl 5):S421-S424.
[11] Fujii T, Shimono R, Tanaka A , et al. A case of suspected adverse reactions to sirolimus in the treatment of generalized lymphatic anomaly[J]. Case Rep Pediatr, 2019,2019:3101357.
[12] Ying H, Qiao C, Yang X , et al. A case report of 2 sirolimus-related deaths among infants with kaposiform hemangioendotheliomas[J]. Pediatrics, 2018,141(Suppl 5):S425-S429.
[13] Goldenberg DC, Carvas M, Adams D , et al. Successful treatment of a complex vascular malformation with sirolimus and surgical resection[J]. J Pediatr Hematol Oncol, 2017,39(4):e191-e195.
Options
Outlines

/

〈 〉